- Home
- LPCN vs CIF Comparison
LPCN vs CIF Comparison
Compare LPCN & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPCN | CIF |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 31.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LPCN | CIF |
|---|---|---|
| Price | $3.11 | $1.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 47.6K | 43.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,322,693.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.52 | $1.47 |
| 52 Week High | $5.50 | $1.77 |
Technical Indicators
Market Signals| Indicator | LPCN | CIF |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 56.06 |
| Support Level | $2.98 | $1.68 |
| Resistance Level | $3.39 | $1.75 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 38.78 | 72.07 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.